Vital Therapies Announces Upcoming Fourth Quarter and Full Year 2016 Financial Results Conference Call With Webcast
27. Februar 2017 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Provides Corporate Update
09. Januar 2017 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Third Quarter Financial Results
03. November 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Third Quarter Financial Results Conference Call With Webcast
25. Oktober 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Provides Corporate Update
13. September 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Appointment of Former Receptos President and CEO Faheem Hasnain to Its Board of Directors
15. August 2016 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Second Quarter Financial Results
02. August 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast
21. Juli 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Enrolls First Subject in VTL-308
23. Mai 2016 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, May 23, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces First Quarter Financial Results
09. Mai 2016 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...